A new precision-cardiology spinout (Atrium Therapeutics) raised or received $270 million in cash and equivalents to develop antibody-oligonucleotide conjugates (AOCs) and RNA drugs targeting rare genetic cardiomyopathies, with lead IND plans this year. Separately, Vima Therapeutics extended its Series A to $100 million as it adds Parkinson’s disease to its pipeline after proof-of-concept in isolated dystonia. Both financings underscore investor appetite for organ-targeted RNA delivery and small-molecule approaches to movement disorders. Executives cited clear unmet needs, defined IND timelines and platform leverage as drivers of investor support.